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Summary. To date, all risk assessment studies on ben-
zene have been based almost exclusively on epidernio-
logical data. Wehave attempted a more integrated and 
quantitative evaluation of carcinogenic risk for hu-
rnans, trying to utilize, in addition to the epidemio-
logical data, all data available, specifically data on me-
tabolism, genotoxicity, and carcinogenicity in small 
rodents. An integrated evaluation of the globality of 
the available data seems to suggest a progressive satu-
ration of metabolic capacity both for man and rodents 
between 10 and 100 ppm. The most susceptible target 
cells seem tobe different in humans (predominant in-
duction of myelogenous leukemia) and small rodents 
(induction of a wide variety of tumors). Nevertheless, 
both epidemiological and experimental carcinogenic-
ity data tend to indicate a flattening ofthe response for 
the highest dosages, again suggesting a general Satura-
tion of mechanisms of metabolic activation, extended 
to different target tissues. From a quantitative point 
of view, the data suggest a carcinogenic potency at 10 
ppm two to three times higher than that computable 
by a linear extrapolation from data in the 100 ppm 
range. These observations are in accord with the re-
cent proposal of the European Economic Community 
of reducing benzene time-weighted average occupa-
tionallevels from 10 to 5 ppm. 
Key words: Benzene- Risk estimation- Carcinogenic-
ity- Genotoxicity- Metabolism saturation- Dose-re-
sponse relationship 
Introduction 
Benzerreis probably the chemical with the largest pro-
duction and utilization in the world (IARC 1982 a). As 
a consequence, both occupational exposure and en-
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virenmental contamination occur to a rather signifi-
cant extent. Benzene has been recognized for many 
years as a carcinogen in humans with the induction of 
acute myelogenous leukemia (IARC 1982a). The 
most common regulatory standard for occupational 
exposure in industrialized countries is a Iimit of 10 
ppm (time-weighted average TW A) (IARC 1982a). 
For the corresponding risk assessment often only epi-
demiological data have been considered (IARC 
1982a). Cerrelations with carcinogenicity data in ro-
dents have less frequently been established (Lee et al. 
1983). 
In this paper, we have tried to enrich current in-
formation by compiling the data related to genotoxic-
ity versus nongenotoxicity in the mechanisrn of action 
of benzene, by comparing metabolism in humans and 
rodents, and by pharmacokinetic considerations of a 
possible saturation of benzene metabolism and geno-
toxicity at higher exposure Ievels. 
Epidemiological data 
In the annex to the IARC Monographs on the Evaluation ofthe Car-
cinogenic Risk of Chemieals to Humans, vol29 (IARC 1982b), a 
working group attempted a quantitative risk estimation for benzene, 
based entirely on human epidemiological data. Minimum estimates 
of 14-170 excess leukemia deaths per 1000 workers exposed over a 
working lifetime were calculated for an exposure Ievel of 100 ppm. 
Their computations were based on three epidemiological studies (Vi-
gliani 1976; Ott et al. 1978; Rinsky et al. 1981) for which ranges of 
excess cases and exposure Ievels are shown in Fig. 1. Using the words 
ofthe authors (IARC 1982 b): "The working group found that quan-
titative estimation was more feasible than seemed initially to be the 
case. The group was impressed that rather !arge amounts of quanti-
tative information could be extracted from the published epidemio-
logical data and that reasonable risk estimations could then be based 
on that information." 
The IARC estimate is in rather good agreernent with the esti-
mate of Goldstein (1985). The lifetime risk per parts per million com-
puted by this author was apparently about 10 times higher than the 
lifetime risk computed by the IARC Group. The difference is only 
apparent and due to the fact that in the Goldstein computations a 
continuous life exposure was considered, whereas in the computa-
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Fig.l. Leukemia incidence in workers exposed to benzene (computa-
tions made by IARC Warking Group, IARC 1982 a). Ranges ofben-
zene concentration include variations in exposure Ievels and uncer-
tainty in analytical determinations perfonned by "old" methods 
which bad a precisio,n of ±50% (Rinsky et al. 1981) 
tions ofthe IARC Group the exposure was referred to 40 hfweek for 
45 years. When the computations of Goldsteinare corrected accord-
ing to the standard of exposure utilized by the IARC Group, the ex-
cess cases ofleukemia deaths expected for 100 ppm become 332/1000 
workers, in good agreement with the value deduced from Fig. 1. In 
the Goldstein computations, two out of three epidemiological stud-
ies were the same as those utilized by the IARC Group. 
Carcinogenicity in animals 
To our knowledge, the first suggestion that benzene 
could be carcinogenic in small rodents came from 
work published in 1979 by Maltoni and Scarnato. The 
induction of Zymbal gland carcinoma in female rats 
was statistically significant (P = 0.0031) at 250 mg/kg 
(administered by gavage once daily, 4--5 days each 
week, for 52 weeks). 
A suggestion that benzene could be carcinogenic in 
small rodents upon inhalation came from a work pub-
lished in 1980 by Snyder et al. Benzene was given to 
C57BL/6J mice at a concentration of 300 ppm, 6 h/ 
day, 5 daysjweek, for life. Eight hematopoietic tumors 
were found in 40 treated animals, whereas only 2 were 
found in 40 controls. The difference was suggestive 
but only borderline from a statistical point of view 
(P=0.044, one-tailed, according to the Fisher exact 
test). 
After the publication in 1982 of the work of the 
IARC group on quantitative cadcer risk estimation 
based only on epidemiological data (IARC 1982 b), 
the carcinogenicity of benzene in small rodents was 
better defined und confirmed (NTP 1984; Cronkite et 
al. 1985; Maltoni et al. 1985). An overall picture ofthe 
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results that we have considered relevant is presented in 
Table 1. Differences in strain susceptibility and in 
route of administration can be observed: Sprague-
Dawley rats are less susceptible than Fischer 344 rats 
to benzene administered by gavage. A quantitative 
comparison of the carcinogenicity results from oral 
with inhalation exposure could not be made because 
we could not find enough data on serum levels ofben-
zene at different concentrations and times after begin-
ning of treatment. 
If we confine ourselves to the high dose inhalation 
experiments of Maltoni et al. (1985), we can compute 
a tumor incidence over controls (animals with at least 
one tumor) of 0.27 for an average continuous concen-
tration (on the basis of8hfday, 5 days a week) of243 
ppm for 2 years [a different value (TWA=284ppm) is 
reported in the legend of Table 1, but this value 
refers to a daily exposure of 4 h for 7 weeks plus 
7 h for 97 weeks], equivalent approximately to an 
incidence over controls of 111/1000 animals for 
100 ppm for rat lifespan. If we consider the inhala-
tion experiment with mice of Snyder et al. (1980), 
we can compute a tumor incidence over controls 
of 0.15 for an average continuous concentration 
of 225 · ppm for 2 years, equivalent approximately to 
an incidence over controls of 67/1000 animals for 100 
ppm for mouse lifespan. Considering carcinogenic po-
tencies can span a range ofmore than 107 times (Parodi 
et al. 1982; Peto et al. 1984), a difference by a factor 
A 
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Oeily dosoge of Benzone edminlstered to mice and rats 
Fig. 2. Oncogenic potency index (OPI) as a function of dosage ofben-
zene in mice and rats. OPI= -1n(1-l)/Dt, where Iis the excess inci-
dence over controls (proportion of animals with at least one malig-
nant tumor for all tumors), t is the length of observation (time unit = 
2 years) and D is the dosage in millimoles per kilogram per day 
equivalent to the total dose divided by a 2-year exposure (Parodi et 
al. 1982). Only dosages which produced statistically significant ef-
fects (P<O.OS) were considered. These data arenot directly compa-
rable with those of Table 1 where malignant tumor incidences of dif-
ferent targetargans are reported. A = F344 rats, gavage (NTP 1984); 
B=B6C3F1 mice, gavage (NTP 1984); C=S-D rats, gavage (Mal-
toni et al. 1985) 
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Table l. Malignant tumors observed in long-term assays of benzene carcinogenicity in rodents 
Species Route of administration 
Inhalation Ga vage 
Main target Tumor TWA Re- Strain Main target Tumor Chronic Re- Strain 
organsa incidence chronic sponse organs8 incidence dose sponse 
over dose over (mgfkg 
controls (ppm) controls perday) 
Rat Zymbal glands 0.093 284 (+ +) S-Db Zymbal glands 0.22 100 (+ +) F344" 
Oral cavity 0.079d 284 (+ +) S-Db Zymbal glands 0.42 500 (+ +) S-Db 
Liver (hepatomas) 0.108d 284 (+ +) S-Db Oral cavity 0.19 50 (++) F344e 
Breast 0.084d 284 (+) S-Db Oral cavity 0.52 500 (++) S-Db 
Nasal cavity 0.021 284 (+) S-Db Li ver 0.063 500 (+) S-Db 
( angiosarcoma) 
Skin 0.23e 500 (+) S-Db 
Skin 0.16e 200 (+) F344e 
Nasal cavity 0.05 500 (+) S-Db 
Forestomach 0.15d 500 (+) S-Db 
(in situ ca.) 
Mouse Hematopoietic 0.15e 300 (±) C57BL/68 Zymbal glands 0.24 100 (++) B6C3F1 c 
systemr 
Hematopoietic 0.145d 300 (+) C57BL/6h Li ver ( adenomas + 0.14d 100 (+ +) B6C3F1 c 
systemr carcinomas) 
Ovary 0.09d 300 (+) C57BL/6h Hematopoietic 0.16 25 (+) B6C3Ft• 
systemr 
Zymbal glands 0.17d 300 ( +) C57BL/6h Breast 0.275d 500 (+) Swissb 
Lung(adenomas) 0.22 500 (+) Swissb 
a Tumor incidence in treated groups was higher than that of controls from a statistical point ofview (P<0.05). Only the most effective dosage 
was reported 
b Maltoni et al. (1985). In inhalation studies, S-D rats were exposed to benzene pre- and postnatally [4-7 h/day, 5 daysjweek for 104 weeks 
(TWA=284ppm) or 15 weeks (TWA=200ppm)]. Experiments with Wistar rats and Swiss mice are ongoing (100-week study). Tumor 
incidences from this work have been calculated by referring the number of tumor-bearing animals to the correct number (i.e., the number of 
survivors at the time that the first tumor appeared, regardless of the organ considered) 
• NTP study (1984). Malignant tumors of Jung, breast, and preputial glands were also induced 
d Only in females 
e Only in males 
r Malignant Iymphomas 
8 Snyder et al. (1980). Mice were exposed for 6h/day, 5 dayjweek for life. A singledosewas tested 
h Cronkite et al. (1985). Subchrome exposure (16 weeks) and 99-week observation. A singledosewas tested 
TWA = time-weighted average. F344 =Fischer 344 rats. S-D = Sprague-Dawley rats. ( + +) = dose-related tumor induction. ( +) =dose-
unrelated tumor induction. ( ±) = borderline evidence of tumor induction (0.1 > P> 0.05) 
of 2 to 5 between small rodents and humans is remark-
ably small. Obviously, in making this statement we 
imply that the ratio of tumor latency to lifespan is es-
sentially the same for both humans and small rodents. 
Most experimental evidence seems to favor this broad 
assumption (behind this apparently simple hypothesis 
very complex problems are hidden when considering 
carcinogenesis as a multistep process. Mutation-like 
events seem to have a similar frequency in human and 
rodent cells, but perhaps the number of steps is differ-
ent in the two species, in order to adjust latency to the 
respective lifespan). The dosage extrapolations at low 
Ievels of risk, perfonned by the USA Environmental 
Protection Agency (Lee et al. 1983; Goldstein 1985), 
showed a similar picture of concordance between hu-
man and animal data. 
From the point of view of overall tumor frequency 
small rodents and humans showed very similar sensi-
tivity. Considering target organ, only few leukemias 
(usually not of the myeloid type) were induced in ro-
dents. Zymbal glands and oral cavity were the primary 
targets in rodents, but neoplastic effects were also ob-
served in liver and breast, and occasionally in skin, 
nasal cavity, Jung, forestomach, adrenals, ovary, Har-
derian and preputial glands (Table 1). We are aware 
that the application of animal data (as proposed here) 
to humans would be safer if not only a quantitative 
but also a qualitative similarity of tumor incidences 
bad been shown in the two systems. 
Some indication of a possible dose-response rela-
tionship is affered by the experiments when benzene 
was given by gavage. In Fig. 2 the oncogenic potency 
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Table 2. Short-term assays of potential carcinogenicity of benzene: evaluation of most genotoxicity data from literature. Figures indicate the 
number ofshort-term assays which were either positive ( +) or negative (- ). Unless otherwise indicated, data are taken from IARC (1982a,c), 
ECETOC (1984) and Dean (1985) reviews. Data lacking in experimental details, equivocal for the authors or for IARC working group, or 
successively changed by the same authors after having modified experimental design, have not been considered 
Endpoint DNA darnage Mutation 
System (+) (-) (+) 
Prokaryotes 0 pol A 2 0 ST 
0 ST,BS 
0 ST 
Fungi/green plants 0 SC 
Sb GM,GC,CO 
2 TRD 
lnsects 0 RM 
1b RM 
Amphibians 
Mammalian cells 1 c MtMBI 0 0 L5178Y 
(in vitro) 1d MMBI 0 6b L5178Y,V79, 
p AE 2b CHO,HL 
2b UDS 4b 
Mammals (in vivo) 1 e 1f 0 
28 0 
Rumans (in vivo) 
Class positivity: 8/17=47.1% 14/58 = 24.1% 
Overall activity (positive tests/total tests): 
a From Lee et al. (1983) 
b From Table 1 of ICPS collaborative study of Ashby et al. (1985) 
c From Kalf et al. (1985) 
d From Arfellini et al. (1985) 
e From Parodi et al. (1983) alkaline elution 
r From Parodi et al. (1983) viscosimetric unwinding 
g From Lutz and SchlaUer (1977b) and Arfellini et al. (1985) DNA adducts 
b Point mutation in rat chromosomes 
1 From Gad-el-Karim et al. (1984) 
J From Choy et al. (1985) 
Chromosome 
an omalies 
(-) (+) (-) 
p 
7 
5b 
1 3b A 1b 
16b 
0 
1 
2b 
p CA 0 
1 A 0 
9b 1 a CA 0 
7 CA 1 
3b CA 4b 
2b A/P 3b 
2 SCE 1 
0 SCE 6b 
0 MN 1b 
1b 13 CA 1 
1 i CA 0 
2 SCE 0 
11 MN 0 
1 j MN 0 
19 CA 2 
48 CA 0 
0 SCE 2 
71/93=76.3% 
96/180 = 53.3% 
Other 
(+) (-) 
0 MC 3b 
3b TR Sb 
0 DL 
3/12=25.0% 
CHO=Chinese hamster ovary. ST=Salmonella typhimuriumfmicrosome. BS=Bacillus subtilis. SC=Saccharomyces cerevisiae. GM=gene 
mutation. GC=gene conversion. CO=crossing-over. A=aneuploidy. RM=recombination and mutation. CA=chromosome aberration. 
MtMBI = mitochondria-mediated binding to mitochondrial DNA. MMBI =microsome-mediated binding to calfthymus DNA. AE = alkaline 
elution. UDS =unscheduled DNA synthesis. HL =human lymphocytes. P = polyploidy. SCE = sister chromatid exchange. MN= micronucleus 
test. MC = metabolic cooperation. TR = cell transformation. DL =dominant lethaltest (rat). pol A = DNA polymerase-deficient and proficient 
Escherichia coli. TRD = Tradescantia assay 
index (OPI) computed according to Parodi et al. (1982) 
for increasing benzene dosages is reported, and sug-
gests a higher relative sensitivity to the carcinogenic 
effect of benzene at lower dosage. Carcinogenicity 
data in rodents for vinyl chloride given by inhalation 
also showed typical flattening of the response at the 
highest dosages (Maltoni 1975). However, in the 
case of benzene, dose-response experiments with in-
halation exposure are not available. A quantitative 
correlation between human and animal data was 
reported by Rall ( 1977) for chlornaphazine, benzidine, 
diethylstilbestrol, and tobacco smoke. 
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Short-term tests 
The qualitative results obtained with short-term as-
says are illustrated in Table 2. As is typical of a com-
pound examined in many different short-term tests 
and in many laboratories, there are a mixture of posi-
tive and negative results. In order to express a global 
opinion on the data, we have followed the approach 
suggested by Ashby et al. (1985). These authors have 
examined the results obtained with short-term tests, 
performed in 66 different laboratories, on 10 different 
chemicals. Clearly genotoxic and carcinogenic com-
pounds like acrylonitrile and toluidine were positive in 
40%-60% of the tests. Presumed noncarcinogens 
and/or nongenotoxic compounds like benzoin and ca-
prolactam were positive in about 20% ofthe tests. The 
authors suggested that potent carcinogens with a 
genotoxic mechanism would be positive in "'80% of 
the tests. Noncarcinogens could be positive in -20% 
ofthe cases. Weak carcinogens should produce an in-
termediate number of positive responses. 
We examined all the data that could be collected on 
benzerre without any selection or exclusion of data. 
Benzene appeared positive in 53% of the cases 
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(Table 2). In the perspective of the above consider-
ations, the results are definitely more typical of a geno-
toxic carcinogen than of a noncarcinogen or nongeno-
toxic agent. However, looking at the results in more 
detail, the percent of positivity of DNA darnage data 
was 47%, whereas for point mutations and chromo-
somal anomalies the values were 24% and 76°/o, re-
spectively (Table 2). lt seems reasonable that there 
might be something peculiar in the DNA darnage in-
duced by benzene, in the sensethat the darnage seemed 
clearly more clastogenic in vivo and in vitro than mu-
tagenic. Wehave examined the publications available 
on chromosomal darnage induced by benzene in ro-
dents in terms of dose-response relationship after 
treatment in vivo (Erexson et al. 1984; Gad-el-Karim 
et al. 1984; Styles and Richardson 1984; Choy et al. 
1985). The results obtained are shown in Table 3. The 
potency of the response (effectfdosage) clearly de-
creased from low to medium to high dosage. In the ex-
periments where benzene was given by inhalation 
(Erexson et al. 1984; Stylesand Richardson 1984) the 
net effect was only doubled when the exposure in-
Table 3. Dose-response relationship for the clastogenic activity of benzene in rodents 
Species Route of Endpoint and Effect8 /dosage ratio at different dosage 
administra- dose unit 
tion Low Medium High 
Male Swiss Oralb Micronuclei/1 000 PCE 4-2.4 0.18 6-2.4 =0.04 
28.7-2.4 0.03 
mice mg/kg 8.8• 88 880 
Oralb Chromosome aberrations . 0.06-0.03 0.0034 0.16-0.03 =0.0015 
1.1-0.Q3 0.0012 per metaphase, mgfkg 8.8t 88 -- 880 
Male B6C3F1 Orald Micronuclei/1000 NCE 2.5-1.2 
=0.052 5.8-1.2 =0.046 9.3-1.2 0.013 
mice mg/kg 25• -- 100 600 
Male Wistar Inhalation' % cells with chromosome 3.03-1.54 0.15 4.45-1.54 0.030 7.81-1.54 0.0063 
rats anomalies, ppm 108 100 1000 
Male DBA/2 Inhalationh SCE/metaphase 7.6-5.9 0.17 9.5-5.9 =0.036 13.8-5.9 0.0079 
mice ppm 10i 100 1000 
Inhalationh Micronuclei/1000 PCE 0.9-0.21 0.069 2.03-0.21 0.018 2.81-0.21 0.0026 ppm 101 100 1000 
a Treated values minus control values 
b Two doses were administered 24 h apart and animals were sacrificed 30 h after the frrst dose (Gad-el-Karim et al. 1984) 
c Corresponding to 3.76 ppm according to EPA computations (Lee et al. 1983), assuming a respiratory absorption coefficient of 0.5 and a 
ventilation capacity of 0.031/min for mouse (Gold et al. 1984) 
d Subehrenie treatment within NTP study (1984). Micronuclei were measured after exposure for 5 daysjweek for 4 months (Choy et al. 1985) 
• Corresponding to 10.7 ppm according to EPA computations (Lee et al. 1983), assuming a rcspiratory absorption coefficient of 0.5 and a 
ventilation capacity of 0.031/min for mouse (Gold et al. 1984) 
r Exposure of 6 h (Styles and Richardson 1984) 
8 Corresponding to 7.1 mgfkg according to EPA computations (Lee et al. 1983), assuming a respiratory absorption coefficient of 0.5 and a 
ventilation capacity of 0.11/min for rat (Gold et al. 1984) 
h Exposure of 6 h (Erexson et al. 1984) 
1 Corresponding to 23.4mgfkg according to EPA computations (Lee et al. 1983), assuming a respiratory absorption coefficient of0.5 and a 
ventilation capacity of 0.031/min for mouse (Gold et al. 1984) 
PCE = polychromatic erythrocytes. NCE = normochromatic erythrocytcs. SCE = sister chromatid exchanges 
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Table 4. Rank classification of potency of oncogenicity (OPI) and of DNA damaging activity (CBI) for 36 carcinogens tested in rat and mousea 
and for benzene 
Rank Log10 OPI Log10 CBI Rank Log10 OPI Log10 CBI 
-1.42 Anil -0.35 Eth 19 2.66 CP 2.06 NHMI 
--+ 
--+ 2 -0.96 AAB -0.30 DES 20 2.72 MDAB 2.07 NPI 
3 -0.78 CC14 0.21 2-NA 21 2.73 ENU 2.14 DEN 
--+ +----
4 -0.56 MMS 0.38 AAB 22 2.96 BP 2.16AAT 
--+ 
--+ 5 0.00 CHC13 0.45 MCA 23 2.97 DEN 2.25 NPY 
6 0.34 2-NA 0.57 Anil 24 3.01 AAF 2.26 Benzid 
7 1.26 NPY 0.83 DAB 25 3.05 HAAF 2.26 EDB 
8 1.40 Eth 0.86 CHC13 +---- 26 3.06 EC 2.29 ENU 
9 1.57 EDB 1.18BP - 27 3.07 Benzid 2.59 HAAF 
10 1.61 DAB 1.35 DMBA 28 3.13 DMN 2.60 MMS 
11 1.65 DMH 1.41 CC14 29 3.43 MNU 2.71 MNU 
12 1.79 NPI 1.61 EC 30 3.52 DES 2.75 AFB2 
13 2.12 NM 1.64 NM 31 3.60 NMust 2.83 AFG1 
14 2.14 AAT 1.79 CP 32 3.73 NHMI 3.00MNNG 
15 2.23 MNNG 1.79 EMS 33 3.73 MAMA 3.40 DMH 
16 2.33 MCA 1.82 MDAB 34 3.95 AFG1 · 3.47 DMN 
17 2.35 AFB2 1.92 NMust 35 4.36 DMBA 3.64 MAMA 
18 2.50 EMS 2.03 AAF 36 4.41 AFB1 4.09 AFB1 
Benzene: OPI values = 0.82b, 0.23c, 0.88d, 0.086 8 , 0.056r; Log10 OPI = -0.086b, -0.638c, -0.056d, -1.09e, -1.25r 
CBI values = 78, 1.7h, 151; 
a Data from Parodi et al. (1982) 
b F-344 rats, gavage (NTP study 1984) 
c S-D rats, gavage (Maltoni et al. 1985) 
d B6C3F1 mice, gavage (NTP study 1984) 
c Swiss mice, gavage (Maltoni et al. 1985) 
r Wistar rats, gavage (Maltoni et al. 1985) 
8 Wistar rats, i.p. (Arfellini et al. 1985) 
Log10 CBI = 0.8458, 0.23h, 1.176i 
h SIV~50 rats, inhalation (Lutz and Schlatter 1977b). Exposure in a closed inhalation chamber: the amount ofbenzene administered was known 
1 BALB/c mice, i.p. (Arfellini et al. 1985) 
Arrows indicate the rank positions of log10 OPI and of log10 CBI of benzene 
Anil=aniline. AAB=4-aminoazobenzene. CC14 =carbon tetrachloride. MMS=methyl methane sulfonate. CHC13 =chloroform. 
2-NA = 2-naphthylamine. NPY = N-nitrosopyrrolidine. Eth = ethionine. EDB =ethylene dibromide. DAB = N,N-dimethyl-4-aminoazobenzene. 
DMH = 1,2-dimethylhydrazine. NPI = N-nitrosopiperidine. NM= N-nitrosomorpholine. AA T = o-aminoazotoluene. MNNG = N-methyl-N'-
nitro-N-nitrosoguanidine. MCA=3-methylcholanthrene. AFB2=aflatoxin B2 • EMS=ethyl methane sulfonate. CP= cyclophosphamide. 
MDAB = 3' -methyl-4-dimethylaminoazobenzene. ENU = N-nitrosoethylurea. BP = benzo(a)pyrene. DEN= diethylnitrosamine. AAF = 2-
acetylaminofluorene. HAAF = N-hydroxy-2-acetylaminofluorene. EC = ethyl carbamate. Benzid = benzidine. DMN = dimethylnitrosamine. 
MNU = N-nitrosomethylurea. DES= diethylstilbestrol. NMust = nitrogen rnustard. NHMI = nitrosohexarnethyleneimine. MAMA= rnethyl-
azoxymethanol acetate. AFG1 =aflatoxin 0 1• DMBA= 7,12-dimethylbenz(a)anthracene. AFB1 =aflatoxin B1 
creased 10-fold from 10 to 100 ppm. In their work on 
micronuclei induction in polychromatic erythrocytes 
. of CD-1 mice Hite et al. (1980) reported very large 
fluctuations in each time group afteroral treatment, 
but the averagetrendwas flattening of the response 
above 110 mg/kg, corresponding to approximately 47 
ppm accordip.g to EPA computations (Lee et al. 1983) 
(see also legend ofTable 3). 
Carcinogenic potency of mutagens in rodents 
seems to correlate semiquantitatively with adduct for-
mation in liver DNA. In 1979 Lutz proposed an index 
ofpotency, the covalent binding index (CBI) for DNA 
adducts. In 1982, Parodi et al. discussed a procedure 
for the transformation of carcinogenicity data in 
terms of potency coefficient, OPI, which is, as a first 
approximation, the reciprocal of the TD 50 index of 
Peto et al. (1984). From a database of carcinogenic po-
tency (OPI) and liver DNA adducts in vivo (CBI) that 
we had published previously (Parodi et al. 1982) we 
wete able to find a group of 36 chemieals for whlch 
both OPI and CBI data were available. These data, in 
ascending rank of potency are presented in Table 4. 
Potency data concerning benzene were inserted at the 
appropriate places, between the 1st and s•h position for 
OPI values and between the 3rd and 9'h position for 
CBI values. For both OPI and CBI values benzene 
ranked amongst the weakest chemieals on the scales of 
potency. The data seem to suggest not only a qualita-
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tive correlation between carcinogenicity and adduct 
formation but also some degree of quantitative corre-
lation. 
Kinetics and metabolism 
In humans, following benzene exposure at relatively 
low concentrations (amount of absorbed benzene 
......,4-10 mglkg) (Teisinger et al. 1952; Nomiyama and 
Nomiyama 1974a, b), about 113 is expired unchanged 
in the air and 2 I 3 is excreted as metabolites in the urine 
within 24-48 h. Approximately 87% is excreted as 
conjugates of phenol, 9% as conjugates of catechol, 
and 3% as conjugates ofhydroquinone. In Swiss mice 
injected s.c. with 440 or 880 mglkg benzene, approxi-
mately 2 I 3 or 3 I 4 , respectively, is excreted unchanged 
in the air, and 1 I 3 or 1 I 4 , respectively, is excreted as 
metabolites in the urine within 24 h (Andrews et al. 
1977). Other studies on the urinary metabolites in 
mice (Longacre et al. 1981), have indicated that 81% 
is represented by phenol, 15% by catechol, and 4% by 
hydroquinone. Trace amounts of trans-tr~.ns muconic 
acid and of 1 ,2,4-trihydroxybenzene have also been 
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Fig. 3. Benzene concentration in the closed inhalation chamber as a 
function of time after injection of benzene into the chamber. In 
phase I, the major phenomenon is uptake and distribution of ben-
zene in the rat. In phase II, benzene concentration decreases, es-· 
sentially by zero order kinetics. In phase III, a shift to 151 order kin-
etics occurs 
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detected. Benzoquinones are, possibly, the electro-
philic reacting intermediates; involvement offree radi-
cal mechanisms in phenol production has also been 
postulated (J ohansson and Ingelman-Sundberg 1983). 
The same metabolites and similar ratios have been 
found in the urine of many other mammals (IARC 
1982 a), which suggests that the major pathways of 
benzene metabolism are similar in all mammalian spe-
cies tested so far. 
In view of these considerations it seems acceptable 
to utilize the information obtained from experimental 
data (both short-term tests, metabolism, and pharma-
cokinetics) for an investigation of the relationship be-
tween dose and effects. In order to investigate the kin-
etics of uptake and metabolism of benzene by inhala-
tion, adult male SIV-50 rats (270-340 g) were exposed 
to benzene evaporated in a closed inhalation system (a 
21 desiccator) which has been described in detail else-
where (Lutz and Schlatter 1977 a). In this system, ex-
pired carbon dioxide was adsorbed on soda lime and 
replaced by pure oxygen to keep the total pressure at 
a constant Ievel. A typical time-course of benzene con-
centration in the desiccator is shown in Fig. 3: similar 
pattems were obtained for the experiments reported in 
Fig. 4. During the first 2 h, the benzene concentration 
in the air rapidly decreased until an equilibrium was 
reached between absorption and exhalation. Within 
2 h, about 90% of the total arilount of benzene had 
been taken up by the rat, about 10% was in the air. 
In a secend phase, the Ievel ofbenzene in the chamber 
decreased slowly, always in equilibrium with the inter-
nallevel of benzene so that the rate of the metabolic 
turnever could be estimated from the decreased ben-
zene concentration in the air . 
U sing different doses of benzene, the phase II data 
were analyzed for the period of time required to halve 
the benzene concentration determined at 2 h. The re-
sults are shown in Fig.4. In the range 200-1200 ppm 
(0.6-3.8 mgll), the ''halflife" ofbenzene was not a con-
stant value but seemed to increase linearly with ben-
zene concentration in the air. This suggests a zero 
order reaction, as if the overall metabolic system was 
saturated and working at a maximum const~nt speed. 
A regular feature of the experiments reported in Fig. 4 
was the presence of a phase 111, as reported in the ex-
ample of Fig. 3: starting from about 50-30 ppm and 
below, the system was no Ionger saturated and first 
order decay of benzene Ievels was regularly observed. 
Other findings seemed to confirm the observation 
that the rate of benzene metabolism is progressively 
saturated and flattened at concentrations above 30 
ppm. The results of Andrews et al. (1977) seemed to 
indicate the same, when mice (30 g) were given 3H-
benzene s.c., one group receiving 440 mglkg and an-
other group receiving 880 mglkg. The metabolites in 
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urine were measured over a 24-h period. The micro-
mole equivalents of benzene found as metabolites in 
the urine were similar (60.1 and 72.6), irrespective of 
doubling the dose. Again, metabolic processes were 
saturated. Furthermore, rats inhaling benzene con-
centrations of 125, 250, 625, or 1250 ppm for 6 h ex-
creted similar amounts of phenol in urine: hence ben-
zene metabolism was already eapacity-limited at 125 
ppm (Gut and Frantik 1980). 
Although no appropriate metabolism experiments 
are available in humans, the epidemiological data on 
the tumor incidence seem to suggest a flattening of the 
dose-response curve, for concentrations above 50 ppm 
(Fig.1). 
Conclusions 
The quantitative concordance between experimental 
data and epidemiological data seems to allow some 
degree of utilization of experimental results in human 
risk estimation. A few years ago, in response to the 
publication of the IARC report on benzene (IARC 
1982b) it was hotly debated (Sun 1982; Tomatis 
1982) whether a linear extrapolation from 170 excess 
leukemia deaths (for a working lifetime exposure to 
100 ppm) to 17 excess deaths (3 times background 
risk) for a 10 ppm exposure could be defensible. 
Wehave presented evidence that nonlinear dose-
response relationships suggested by the data on tumor 
induction in animals and man and on chromosomal 
darnage in rodents might be explained by the metabo-
lism of benzene which seems to become sahirated in 
the dose range analyzed. A similar situation has. been 
described previously for vinyl chloride where it was 
shown that metabolism (Gehring et al.1978), macro-
molecular binding (Watanabe et al. 1978), and tumor 
induction (Maltoni and Lefemine 1975) allbecome 
S. Grilli et al.: Risk estimations for benzene 
Fig. 4. Reciprocal rate of benzene 
consumption in rats exposed to increasing 
concentrations of benzene (phase li of 
Fig. 3) in a closed inhalation cbamber (Lutz 
and Schlatter 1977 a). On the abscissa, tbe 
total amount ofbenzene applied to the 
chamber and expressed per kilogram body 
weight is given along with the corresponding 
concentration in the chamber after 2 h. This 
second scale was obtained from a linear 
regression (y=0.049 + 0.014x, r=0.954, 
n = 8) between benzene concentration 
observed in single experiments and total 
amount of benzene applied 
saturated at inhalation exposure levels between 500 
and 2500 ppm. The threshold with benzene appears to 
be at a lower concentration in the rat (30-50 ppm) and 
it remains to be elucidated whether saturation of ben-
zene metabolism in humans occurs in the same expo-
sure range. Since this cannot be investigated in vivo, 
alternative methods might be required. One possibility 
would be the use ofhuman tissue samples for the study 
of the maximum metabolic capacity in liver and hone 
marrow. 
Because of the flattening of the curves at high ex-
posure Ievels, pro bably due to saturation of the activa-
tion of benzene to reactive metabolites, the data ob-
tained at the lowest exposure should be considered the 
mostrelevant as a basis for an extrapolation. Data ob-
tained from dose Ievels above saturationwill be ofless 
value for defining the shape of the dose-response 
curves in the lower range. lt is inevitable that a 10 ppm 
exposure will result in a higher risk than if the high 
dose data are given the same weight, regardless of the 
model chosen. Our utilization of the available in-
formation tends to suggest that going from 100 ppm 
to 10 ppm for a 45-year exposure the risk could be two 
to three times higher than that expected from a linear 
extrapolation. U sually benzene workers are exposed 
for an average of about 5-10 years and not for 45 
years; therefore, we are dealing with a small increment 
of tumor incidence in comparison with the natural 
background ofl/4 to 1/ 5 cancer-related deaths. ltisin-
teresting to note that the European Economic Com-
munity (COM(85)669 def., Bruxelles, December 3, 
1985) is considering the possibility ofputting the Iimit 
of occupational exposure at 5 ppm instead of 10 ppm, 
as generally accepted by different countries. 
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